Aeglea: Immedica Pharma's Acquisition of Pegzilarginase Assets from Aeglea
Davis Polk & Wardwell advised Immedica Pharma AB on the transaction. Immedica Pharma AB announced its acquisition from Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE) of all assets related [...]
Read full article »
CEO
Aeglea is a pharmaceutical company that researches and develops enzyme-based therapeutics for the treatment of cancer and rare genetic diseases.
Read more